The integration of liquid biopsies and circulating tumor DNA (ctDNA) analysis will further allow for real-time monitoring of resistance mechanisms, improving treatment adaptability and precision oncology approaches in B-RAF-mutant cancers [57]. Here, BRAF is linked to neoplasm.